This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ThromboGenics Opens New U.S. Headquarters

LEUVEN, Belgium, March 5, 2012 /PRNewswire/ --

U.S. Organization Continues to Build Ahead of Ocriplasmin's Planned  Launch

 

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces the opening of its new U.S headquarters. The facility which is situated in Iselin, New Jersey, is the new home to the Company's U.S. organization which is led by Dr. David Pearson, Head of U.S. Country Operations. ThromboGenics has been growing its U.S. team in recent months building its marketing, medical, commercial, market access and regulatory expertise ahead of the Company's planned launch of its lead product ocriplasmin.

ThromboGenics intends to resubmit a BLA for ocriplasmin in the U.S. before the end of April 2012 and expects the product to be granted Priority Review by the FDA. Ocriplasmin will be filed for the treatment of symptomatic vitreomacular adhesion (VMA) including macular hole.

Dr Patrik De Haes, CEO of ThromboGenics, commented: "The opening of our new U.S Headquarters is an important step as we build the first-class organization that we need to successfully launch ocriplasmin in the world's largest healthcare market. We remain on track to resubmit a BLA for ocriplasmin before the end of April for Priority Review. Our U.S. team is expecting a very exciting and highly productive period as it prepares for the anticipated approval of ocriplasmin by the end of 2012."

As a result of its decision to locate its headquarters in Iselin, ThromboGenics will benefit from a Business Employment Incentive grant from the New Jersey Economic Development Authority whose value could exceed $1.0 million over a multi-year period.

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The Company's lead product ocriplasmin has successfully completed two Phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (VMA). The MAA for ocriplasmin has been accepted for review in Europe and the BLA will be re-submitted in the U.S. by the end of April 2012. Ocriplasmin is in Phase II clinical development for additional vitreoretinal conditions.

ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International. These include TB-402 (anti-Factor VIII), a long-acting anticoagulant in Phase II, and TB-403 (anti-PlGF), in Phase Ib/II for cancer in partnership with Roche.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,751.39 +121.12 0.69%
S&P 500 2,108.57 +15.32 0.73%
NASDAQ 5,111.7330 +22.5270 0.44%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs